A Man Let Snakes Bite Him 200 Times. His Blood Inspired a Universal Antivenom.
The goal?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
Our 24-year-old has a mental illness. How can we help without enabling him?
My husband and I disagree about how to best support our 24-year-old son. He was a very gifted student and got into an elite university but dropped out in the middle of his sophomore year after developing delusions that people were trying to poison him. He was hospitalized and later diagnosed with paranoid schizophrenia. He has lived with us on and off since then and is a very different person from the son we once knew. He is often disrespectful and, over the years, sometimes stopped talking to us for a year or more at a time. Those periods were torturous — especially for me as his mother — because we had no way of knowing if he was dead or alive. He's been back in touch recently, but it seems mostly to get our financial help to pay his rent and utilities. My husband worries we're enabling him by continuing to help and feels like he'll never grow up if we keep providing financial support. I worry that if we stop helping, he'll cut off contact again or end up homeless.
Yahoo
an hour ago
- Yahoo
DEA Cannabis Poisoned, Zero Oversight-Massachusetts Lab Scandal: A Case Study in DEA's Regulatory Collapse
Poisoned Cannabis, Zero DEA Oversight The DEA's mission statement is a sham under Thomas Prevoznik's watch. Americans are being poisoned by untested state cannabis operators while terminal patients are denied potential cures. WASHINGTON, D.C. / / July 6, 2025 / The Drug Enforcement Administration (DEA) exists to "prevent, detect, and investigate the diversion of controlled substances while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs". Yet under the leadership of Deputy Administrator Thomas Prevoznik, the DEA's Diversion Control Division has catastrophically failed this mission. Instead of protecting public health, the agency has allowed contaminated cannabis to flood state markets-poisoning consumers-while simultaneously blocking federally compliant pharmaceutical research that could save lives. This is not just bureaucratic incompetence; it is systemic negligence bordering on malpractice. 1. DEA's Mission Failure: Poisoned Cannabis, Zero Oversight The Massachusetts Scandal: A Case Study in Regulatory Collapse In Massachusetts, Assured Testing Laboratories-a facility responsible for testing 25% of the state's cannabis-was caught falsifying safety reports, concealing contamination, and approving products that should have failed for yeast, mold, and microbial toxins. Thousands of tainted products reached consumers, yet the DEA: Took no enforcement action Issued no national recall Failed to intervene despite its mandate to prevent diversion and ensure safety. This is not an isolated incident. Across the U.S., unregulated cannabis markets operate like the "Wild West"-with no federal quality control, no uniform safety standards, and no accountability. The DEA, under Prevoznik, has abdicated its duty, leaving Americans exposed to dangerous products while offering no recourse. 2. Blocking Medical Breakthroughs: The DEA's War on Science While turning a blind eye to contaminated street cannabis, the DEA has actively obstructed federally approved pharmaceutical research. MMJ BioPharma, a company developing cannabis-based treatments for Huntington's Disease and Multiple Sclerosis, has faced seven years of bureaucratic sabotage despite: Holding FDA Investigational New Drug (IND) approvals Securing Orphan Drug Designation for Huntington's therapy Passing DEA security inspections. Yet, Prevoznik's division refuses to grant MMJ a bulk manufacturing license, citing a retroactive "Bona Fide Supply Agreement" (BFSA) requirement that creates an impossible Catch-22: No supplier will sign a contract without DEA approval. DEA won't approve without a signed contract. This obstruction is not just regulatory failure-it's deliberate stonewalling. As MMJ's legal filings reveal, DEA Administrative Law Judges (ALJs) operate in a structurally biased system, where registrants win only 20-25% of cases, and the DEA overturns nearly all pro-registrant rulings. 3. The Human Cost: Patients Suffer While Illicit Markets Thrive The DEA's hypocrisy is staggering: Patients with epilepsy, cancer, and neurological disorders are denied access to standardized, pharmaceutical-grade cannabis112. Meanwhile, unregulated THC products-laced with pesticides, mold, and heavy metals-flood the market, making consumers sick 15. Prevoznik's DEA has created the worst of both worlds:No protection for consumers from tainted pathway for research into life-saving medicines. 4. Time for Accountability: Fire Prevoznik, Overhaul the DEA The solution is clear: Remove Thomas Prevoznik for gross negligence and regulatory malpractice. Transfer cannabis oversight to the FDA/NIH, where science-not stigma-guides policy. Investigate DEA's Diversion Control Division for systemic bias and corruption. As MMJ BioPharma CEO Duane Boise stated: "The DEA's Diversion Control Division, under Prevoznik's leadership, has failed to protect the public, failed to uphold science, and failed to meet even the most basic standards of competence." Fire Thomas Prevoznik: A Call to Action The DEA's mission statement is a sham under Prevoznik's watch. Americans are being poisoned by untested cannabis while terminal patients are denied potential cures. Congress must intervene, the courts must act, and the public must demand accountability. Enough is enough. It's time to end the DEA's obstructionism and put public health over bureaucracy. MMJ is Represented by Attorney Megan Sheahan and Associates CONTACT:Madison Hiseymedia@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
an hour ago
- Wall Street Journal
The MAHA Movement Loves Psychedelics. Should Wall Street?
Just about everyone in the 'Make America Healthy Again' (MAHA) movement seems bullish on psychedelics. Robert F. Kennedy Jr. has spoken favorably about the treatments, and President Trump's surgeon general pick, Casey Means, has described psilocybin therapy (known as magic mushroom) as 'one of the most meaningful experiences of life.' That kind of political enthusiasm might suggest a ripe buying opportunity for investors. But Wall Street and pharmaceutical companies have largely stayed on the sidelines. Questions remain. Chief among them is how to commercially scale treatments that leave patients high for several hours.
